CTXR Citius Pharmaceuticals, Inc.
USHealthcareAs of 2026-08-24
Why CTXR matters now
Citius Pharmaceuticals, Inc. (CTXR) is a US stock in Healthcare. The latest InvestLog snapshot shows $0.58 with -4.13% on the session and $6.4M in market capitalization; recent performance reads 1-month -1.41% and YTD -29.68%.
The latest financial table shown here is Q2 2026, with revenue of $1.7M, net income of $-21.2M, and EPS of $-0.95. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -517.5%.
The latest indexable market news headline is "Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update" from PRNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.20
P/S
1.09
EV/EBITDA
-0.04
DCF Value
$0.93
FCF Yield
-517.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
37.4%
Operating Margin
-1041.4%
Net Margin
-823.3%
ROE
-67.4%
ROA
-34.9%
ROIC
-75.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q2 2026 | $1.7M | $-21.2M | $-0.95 |
| Q1 2026 | $3.9M | $-8.2M | $-0.38 |
| Q4 2025 | $0.00 | $-8.0M | $-0.44 |
| FY 2025 | $0.00 | $-37.4M | $-3.38 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
0.98
Citius Pharmaceuticals, Inc. operates as a specialized pharmaceutical firm concentrating on the development and market introduction of critical care products. Its efforts are particularly directed towards anti-infective treatments supporting cancer care, various prescription medications, and pioneering mesenchymal stem cell therapies. The company is actively advancing five unique products within its pipeline: Mino-Lok: An antibiotic lock solution designed to combat catheter-related bloodstream infections by salvaging the infected central venous catheter. Mino-Wrap: A novel liquifying gel-based wrap aimed at minimizing infections associated with tissue expanders following breast reconstructive procedures. Halo-Lido: A topical formulation that blends a corticosteroid with lidocaine, intended to deliver both anti-inflammatory and numbing relief to individuals suffering from hemorrhoids. NoveCite: A mesenchymal stem cell therapy currently under development for treating acute respiratory distress syndrome (ARDS). I/ONTAK: An engineered fusion protein, combining IL-2 and diphtheria toxin, purposed for the treatment of patients experiencing persistent or recurrent cutaneous T-cell lymphoma. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.